Europe
Clinical-stage gene therapy company Axovant Gene Therapies is changing its name to Sio Gene Therapies, a move that will likely further distance the company from disappointing results of its Alzheimer’s candidate just three years ago.
The interim analysis demonstrated that two doses of the vaccine ranging from 2 micrograms to 12 micrograms per dose, given 28 days apart, were safe, with no vaccine-related serious adverse events.
Amgen and AstraZeneca announced that their Phase III NAVIGATOR trial of Tezepelumab hit the primary endpoint in severe asthma.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 10, 2020.
IntraBio lauched a Phase II expansion study for IB1001 (N-Acetyl-L-Leucine) soon after announcing positive results from the initial “parent” multinational trials for Niemann-Pick disease Type C (NPC).
Calliditas said Nefecon hit its primary endpoint by demonstrating a statistically significant reduction in urine protein creatinine ratio, UPCR or proteinuria, after nine months of treatment.
The pre-specified interim data analysis indicated that the Cabotegravir hit the primary objective of superiority compared to the current standard of care for women.
They caution that as more data is accumulated and analyzed, the efficacy percentage may shift. Nonetheless, it’s extremely promising and there were no serious safety signals.
It was relatively quiet in terms of COVID-19-related clinical trials, but there was still quite a bit of news for trials involving other indications. Here’s a look.
A multi-institutional research team has developed a nasal spray that effectively blocks absorption of the SARS-CoV-2 virus in ferrets with direct contact to infected animals.
PRESS RELEASES